Velocity Nova Sp. z o.o. — Clinical Trial Site

54 Registered trials

19 Currently recruiting

Organisation

Velocity Nova Sp. z o.o.

Location

Lublin, Poland

Identifier

ORG-100050694

Address

Ul. Waclawa Sieroszewskiego 34, 24-100, Poland

Departments

-
.
#616005;Velocity Pulawy
8510:KO-MED Nova Zamosc
Cardiology
Chronic pain
Dermatology Department
General medicine
Gynaecology
KO-MED NOVA Lublin II
Medical Center
miejsce prowadzenia badnia: Velocity Zamość
N/A
NA
Nie dotyczy
Practice
Private Practice
Specialized Physician's Office KO-MED
Velocity Clinical Research - Lublin
Velocity Lublin
Velocity NOVA Staszów
Velocity Puławy
Velocity Staszów
Velocity Zamość

Clinical trials at this site (54)

Search interface

GBS-NN/NN2 (50 μg of each fusion protein [GBS-NN and GBS-NN2] in combination with 500 μg Aluminum as Alhydrogel®) given with and without the… Pending

2023-508563-73-00 Prevention of Group B streptococcus infection 10
A study to evaluate the efficacy, immunogenicity, and safety of an RSV and hMPV VLP vaccine compared with placebo in participants aged 60 ye… Pending

2024-513740-28-00 Respiratory Syncytial Virus and Human Metapneumovirus 5
A clinical trial to assess the safety of EXV-802 and EXV-801 and how well they work to reduce agitation symptoms in people with Alzheimer's … Pending

2024-517388-22-00 Agitation in Alzheimer's Disease Dementia 10
OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
An extension study to investigate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chr… Pending

2025-522983-33-00 Chronic rhinosinusitis with nasal polyps 5
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes Pending

2025-523486-17-00 Obesity 5
Obicetrapib Versus Bempedoic Acid to Treat Dyslipidemia in Patients at High to Very High Cardiovascular Risk Recruiting

2025-524265-24-00 Dyslipidemia at High to Very High Cardiovascular Risk 5 2026-05-21
A study to evaluate the efficacy and safety of subcutaneous amlitelimab on background topical corticosteroids therapy in participants aged 1… Recruiting

2023-508099-12-00 Dermatitis atopic 5 2024-06-20
A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting

2022-501354-10-01 axial spondyloarthritis 5 2023-06-21
Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica… Recruiting

2023-506548-18-00 Dermatitis atopic 10 2022-11-10
HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting

2025-523717-29-00 HFpEF or HFmrEF and obesity 5 2026-04-28
A study to evaluate IPN10200 safety and efficacy in the prevention of episodic or chronic migraine in adults Recruiting

2024-511101-28-00 Episodic Migraine Chronic Migraine 4 2026-02-24
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (SHASTA-10 Study) Recruiting

2024-519712-13-00 Hypertriglyceridemia (HTG) 5 2025-12-08
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure and a weak pumping functio… Recruiting

2024-519525-38-00 Heart failure 5 2025-08-22
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Recruiting

2023-509706-30-00 Heart failure (HF) 5 2024-10-18
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-1) Recruiting

2022-500699-76-00 Active Systemic Lupus Erythematosus (SLE) 5 2023-05-18
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARIT… Ended

2024-515523-11-00 Chronic Weight Management 5 2025-06-09
A Phase 3 study to assess the efficacy, safety, and tolerability of itepekimab (antiIL33 mAb) in participants with inadequately-controlled… Ended

2024-516814-39-00 Chronic rhinosinusitis with nasal polyps 5 2025-05-20
A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended

2024-513210-36-00 Chronic Spontaneous Urticaria 5 2025-04-04
A Clinical Study in which patients with acne vulgaris will receive a new topical drug. The safety and efficacy of the drug will be tested. Ended

2023-510341-19-00 acne vulgaris 5 2024-11-14
A Clinical Study in which patients with acne vulgaris will receive a new topical drug for long term. The safety and efficacy of the drug wil… Ended

2023-510342-24-00 Acne vulgaris 5 2024-11-11